Nykode Therapeutics (NYKD) Personalized cancer vaccine summit presentation summary

Leadership in APC-targeted immunotherapy

• Global leader in antigen-presenting cell (APC)-targeted immunotherapy, focusing on oncology and autoimmune diseases.

• Differentiated platform enables tailored immune responses and robust pipeline de-risked by strong durability and survival data.

• Strategic multiprogram collaboration with Regeneron in oncology and infectious diseases.

• Well-capitalized with $124.6 million in cash as of September 30, 2024.

Pipeline and clinical programs

• Broad pipeline spans early to late-stage cancer, infectious diseases, and autoimmune indications.

• Lead asset VB10.16 targets high unmet needs in cervical and head and neck cancers.

• Individualized cancer vaccine VB10.NEO in clinical trials for multiple recurrent/metastatic cancers.

• Collaboration and licensing agreements with Regeneron cover five programs.

Vaccine technology and mechanism

• Modular vaccine technology enables APC targeting, inducing tailored immune responses via DNA, mRNA, viral vectors, or recombinant proteins.

• Platform induces rapid, robust, and long-lasting CD8 T cell responses against cancer cells.

• Proprietary neoantigen selection algorithm optimizes immune response, with ~53% immunogenic neoepitopes per patient.

• Manufacturing is fast, robust, and cost-effective, with rapid turnaround from biopsy to vaccination.